- Home
- FCAP vs PLX Comparison
FCAP vs PLX Comparison
Compare FCAP & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FCAP
- PLX
- Stock Information
- Founded
- FCAP 1891
- PLX 1993
- Country
- FCAP United States
- PLX United States
- Employees
- FCAP N/A
- PLX N/A
- Industry
- FCAP Savings Institutions
- PLX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- FCAP Finance
- PLX Health Care
- Exchange
- FCAP Nasdaq
- PLX Nasdaq
- Market Cap
- FCAP 161.2M
- PLX 160.2M
- IPO Year
- FCAP 1999
- PLX 1998
- Fundamental
- Price
- FCAP $48.00
- PLX $1.92
- Analyst Decision
- FCAP
- PLX Strong Buy
- Analyst Count
- FCAP 0
- PLX 1
- Target Price
- FCAP N/A
- PLX $15.00
- AVG Volume (30 Days)
- FCAP 14.4K
- PLX 753.1K
- Earning Date
- FCAP 04-25-2025
- PLX 05-09-2025
- Dividend Yield
- FCAP 2.50%
- PLX N/A
- EPS Growth
- FCAP 2.61
- PLX N/A
- EPS
- FCAP 3.65
- PLX 0.04
- Revenue
- FCAP $42,869,000.00
- PLX $53,399,000.00
- Revenue This Year
- FCAP N/A
- PLX $65.02
- Revenue Next Year
- FCAP N/A
- PLX $57.34
- P/E Ratio
- FCAP $12.59
- PLX $79.67
- Revenue Growth
- FCAP 6.35
- PLX N/A
- 52 Week Low
- FCAP $27.10
- PLX $0.82
- 52 Week High
- FCAP $53.85
- PLX $3.10
- Technical
- Relative Strength Index (RSI)
- FCAP 59.97
- PLX 27.68
- Support Level
- FCAP $45.68
- PLX $2.70
- Resistance Level
- FCAP $53.85
- PLX $2.93
- Average True Range (ATR)
- FCAP 2.50
- PLX 0.21
- MACD
- FCAP 0.05
- PLX -0.08
- Stochastic Oscillator
- FCAP 58.00
- PLX 1.82
About FCAP First Capital Inc.
First Capital Inc is the financial holding company of First Harrison Bank. Through its subsidiary, it operates as a federally-chartered savings bank that provides banking services to individuals and business customers across locations in America. The bank offers various loans which include residential loans, construction loans, commercial real estate loans and commercial business loans. It also provides consumer loans such as home equity and second mortgage loans, and automobile and truck loans.
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.